Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q13554: Variant p.Pro139Leu

Calcium/calmodulin-dependent protein kinase type II subunit beta
Gene: CAMK2B
Feedback?
Variant information Variant position: help 139 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Proline (P) to Leucine (L) at position 139 (P139L, p.Pro139Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In MRD54; decreased protein abundance; increased autophosphorylation; decreased neuronal migration. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 139 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 666 The length of the canonical sequence.
Location on the sequence: help QILEAVLHCHQMGVVHRDLK P ENLLLASKCKGAAVKLADFG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         QILEAVLHCHQMGVVHRDLKPENLLLASKCKGAAVKLADFG

Mouse                         QILEAVLHCHQMGVVHRDLKPENLLLASKCKGAAVKLADFG

Rat                           QILEAVLHCHQMGVVHRDLKPENLLLASKCKGAAVKLADFG

Bovine                        QILEAVLHCHQMGVVHRDLKPENLLLASKCKGAAVKLADFG
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 666 Calcium/calmodulin-dependent protein kinase type II subunit beta
Domain 14 – 272 Protein kinase
Active site 136 – 136 Proton acceptor
Helix 139 – 141



Literature citations
De Novo Mutations in Protein Kinase Genes CAMK2A and CAMK2B Cause Intellectual Disability.
Kuery S.; van Woerden G.M.; Besnard T.; Proietti Onori M.; Latypova X.; Towne M.C.; Cho M.T.; Prescott T.E.; Ploeg M.A.; Sanders S.; Stessman H.A.F.; Pujol A.; Distel B.; Robak L.A.; Bernstein J.A.; Denomme-Pichon A.S.; Lesca G.; Sellars E.A.; Berg J.; Carre W.; Busk O.L.; van Bon B.W.M.; Waugh J.L.; Deardorff M.; Hoganson G.E.; Bosanko K.B.; Johnson D.S.; Dabir T.; Holla O.L.; Sarkar A.; Tveten K.; de Bellescize J.; Braathen G.J.; Terhal P.A.; Grange D.K.; van Haeringen A.; Lam C.; Mirzaa G.; Burton J.; Bhoj E.J.; Douglas J.; Santani A.B.; Nesbitt A.I.; Helbig K.L.; Andrews M.V.; Begtrup A.; Tang S.; van Gassen K.L.I.; Juusola J.; Foss K.; Enns G.M.; Moog U.; Hinderhofer K.; Paramasivam N.; Lincoln S.; Kusako B.H.; Lindenbaum P.; Charpentier E.; Nowak C.B.; Cherot E.; Simonet T.; Ruivenkamp C.A.L.; Hahn S.; Brownstein C.A.; Xia F.; Schmitt S.; Deb W.; Bonneau D.; Nizon M.; Quinquis D.; Chelly J.; Rudolf G.; Sanlaville D.; Parent P.; Gilbert-Dussardier B.; Toutain A.; Sutton V.R.; Thies J.; Peart-Vissers L.E.L.M.; Boisseau P.; Vincent M.; Grabrucker A.M.; Dubourg C.; Tan W.H.; Verbeek N.E.; Granzow M.; Santen G.W.E.; Shendure J.; Isidor B.; Pasquier L.; Redon R.; Yang Y.; State M.W.; Kleefstra T.; Cogne B.; Petrovski S.; Retterer K.; Eichler E.E.; Rosenfeld J.A.; Agrawal P.B.; Bezieau S.; Odent S.; Elgersma Y.; Mercier S.;
Am. J. Hum. Genet. 101:768-788(2017)
Cited for: INVOLVEMENT IN MRD54; VARIANTS MRD54 29-ARG--GLN-666 DEL; LYS-110; LEU-139; LYS-237 AND GLU-301; CHARACTERIZATION OF VARIANTS MRD54 LYS-110; LEU-139; LYS-237 AND GLU-301; FUNCTION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.